Investment in Subsidiaries (Details Textual) (USD $)	9 Months Ended		12 Months Ended		101 Months Ended	110 Months Ended			12 Months Ended						12 Months Ended		3 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Jun. 30, 2012	Nov. 26, 2008	Jan. 31, 2011 Preferred Class B and C [Member]	Sep. 30, 2010 Calando Pharmaceuticals, Inc [Member]	Jun. 30, 2012 Calando Pharmaceuticals, Inc [Member]	Jan. 31, 2011 Calando Pharmaceuticals, Inc [Member]	Jun. 23, 2009 Calando Pharmaceuticals, Inc [Member]	Nov. 26, 2008 Calando Pharmaceuticals, Inc [Member]	Apr. 17, 2008 Calando Pharmaceuticals, Inc [Member]	Sep. 30, 2011 Ablaris Therapeutics, Inc [Member]	Jun. 30, 2012 Ablaris Therapeutics, Inc [Member]	Jun. 30, 2012 Nanotope, Inc [Member]	Jun. 30, 2012 Leonardo Biosystems Inc [Member]
Investment in Subsidiaries (Textual) [Abstract]
Ownership percentage in subsidiary	100.00%
Aggregate investment in subsidiary through equity and debt														$ 23,200,000
Unsecured Convertible Promissory Note Agreements							2,500,000						2,500,000
Investment in notes offering							200,000						200,000
Additional investment in notes offering							600,000						600,000
Principal amount of note which not converted into shares												500,000
Conversion of notes and accrued interest into share												2,950
Issuance and sold of Common Stock									122,000
Issuance of warrants									26,400
Cash investment in subsidiary											1,000,000
Investment in subsidiary through conversion of intercompany debt											8,100,000
Investment in preferred stock								9,100,000							1,300,000
Stated percentage of notes and advances										10.00%
Percentage of outstanding shares										79.00%						64.00%	23.00%	5.00%
Percentage of investment ownership										76.00%						64.00%	19.00%
Aggregate purchase price of preferred shares			(1,618,509)	(300,000)											2,900,000
Investment in preferred stock by outsider															1,600,000
Amount owed by subsidiary										2,573,403								420,000
Non-cash impairment charge	(1,455,775)					(1,455,775)											1,400,000
Carrying value of the investment																	0
Reserve against receivable																	$ 1,900,000